NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
3.750
-0.130 (-3.35%)
Apr 29, 2026, 12:13 PM EDT - Market open
NervGen Pharma Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 22.07 | 17.27 | 11.66 | 22.45 | 16.93 | Upgrade
|
| Cash & Short-Term Investments | 22.07 | 17.27 | 11.66 | 22.45 | 16.93 | Upgrade
|
| Cash Growth | 27.81% | 48.10% | -48.07% | 32.62% | 202.38% | Upgrade
|
| Accounts Receivable | 0.01 | 0.1 | - | - | - | Upgrade
|
| Other Receivables | 0.08 | 0.42 | 0.25 | 0.03 | 0.06 | Upgrade
|
| Receivables | 0.09 | 0.51 | 0.25 | 0.03 | 0.06 | Upgrade
|
| Prepaid Expenses | 0.39 | 0.29 | 0.11 | 0.08 | 0.07 | Upgrade
|
| Other Current Assets | 0.25 | 0.94 | 0.5 | 0.59 | 0.36 | Upgrade
|
| Total Current Assets | 22.8 | 19.01 | 12.52 | 23.15 | 17.42 | Upgrade
|
| Property, Plant & Equipment | - | - | 0.2 | 0.3 | 0 | Upgrade
|
| Other Intangible Assets | 0.41 | 0.46 | 0.52 | 0.43 | 0.47 | Upgrade
|
| Long-Term Accounts Receivable | - | 0.01 | - | - | - | Upgrade
|
| Total Assets | 23.21 | 19.49 | 13.24 | 23.88 | 17.9 | Upgrade
|
| Accounts Payable | 0.03 | 0.03 | 3.32 | 2 | 0.35 | Upgrade
|
| Accrued Expenses | 4.63 | 4.91 | - | 1.4 | 0.73 | Upgrade
|
| Current Portion of Leases | 0.01 | 0.1 | 0.09 | 0.09 | - | Upgrade
|
| Other Current Liabilities | 15.07 | 11.86 | 11.73 | 6.73 | - | Upgrade
|
| Total Current Liabilities | 19.73 | 16.9 | 15.14 | 10.22 | 1.08 | Upgrade
|
| Long-Term Leases | - | 0.01 | 0.11 | 0.2 | - | Upgrade
|
| Total Liabilities | 19.73 | 16.91 | 15.25 | 10.41 | 1.08 | Upgrade
|
| Common Stock | 103 | 81.19 | 58.93 | 57.41 | 42.4 | Upgrade
|
| Retained Earnings | -146.76 | -102.65 | -78.15 | -55.77 | -35.05 | Upgrade
|
| Comprehensive Income & Other | 47.24 | 24.03 | 17.21 | 11.82 | 9.46 | Upgrade
|
| Shareholders' Equity | 3.48 | 2.58 | -2.01 | 13.46 | 16.82 | Upgrade
|
| Total Liabilities & Equity | 23.21 | 19.49 | 13.24 | 23.88 | 17.9 | Upgrade
|
| Total Debt | 0.01 | 0.11 | 0.2 | 0.28 | - | Upgrade
|
| Net Cash (Debt) | 22.06 | 17.16 | 11.46 | 22.17 | 16.93 | Upgrade
|
| Net Cash Growth | 28.55% | 49.72% | -48.29% | 30.95% | 202.38% | Upgrade
|
| Net Cash Per Share | 0.30 | 0.25 | 0.19 | 0.42 | 0.43 | Upgrade
|
| Filing Date Shares Outstanding | 80.93 | 70.99 | 69.93 | 59.13 | 46.23 | Upgrade
|
| Total Common Shares Outstanding | 79.65 | 70.33 | 59.61 | 58.78 | 46.19 | Upgrade
|
| Working Capital | 3.07 | 2.11 | -2.62 | 12.93 | 16.34 | Upgrade
|
| Book Value Per Share | 0.04 | 0.04 | -0.03 | 0.23 | 0.36 | Upgrade
|
| Tangible Book Value | 3.07 | 2.11 | -2.53 | 13.03 | 16.35 | Upgrade
|
| Tangible Book Value Per Share | 0.04 | 0.03 | -0.04 | 0.22 | 0.35 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.